UPDATE: Eli Lilly's Quarterly Profit Boosted By Newer Products

... Dow Jones News UPDATE: Eli Lilly's Quarterly Profit Boosted By Newer Products Close UPDATE: Eli Lilly's Quarterly Profit Boosted By Newer Products By Val Brickates Kennedy BOSTON (Dow Jones) - Drug maker Eli Lilly & Co.

reported a fourth-quarter profit on Thursday, citing strong sales of newer products, even as sales of its lead product Zyprexa continued to decline.

Fourth-quarter net income was $700.6 million or 64 cents a share, including charges from restructuring and asset impairments.

In the fourth quarter of 2004, the Indianapolis-based company (LLY) posted a net loss of $2.4 million and breakeven earnings per share, due largely to large charges taken for restructuring and the repatriation of foreign profits.

Eli Lilly's adjusted earnings for the fourth quarter were 80 cents a share, compared to 75 cents a share in the year-earlier period.

Sales in the quarter rose 6% to $3.88 billion.

Analysts polled by Thomson First Call had been expecting earnings of 78 cents a share on revenue of $3.9 billion.

Sales of antipsychotic drug Zyprexa - Eli Lilly's most lucrative product - slipped 5% to $1.03 billion for the quarter.

Zyprexa sales have slowed since the drug was linked to the onset of diabetes in certain patients.

The company's core diabetes product line saw an 11% increase in sales to $750 million.

Sales of the oncology drug Gemzar were up 7%, reaching $353 million.

Newer products - such as

Eli Lilly's quarterly profit boosted by newer products

... Investor's Business Daily: Breaking News a.Link{ color: #03f; text-decoration:underline; } HOMENEWS, RESEARCH, & ANALYSISIBD® STOCK LISTSHOW TO INVESTIBD® STORE NEWS, RESEARCH & ANALYSIS Today in IBD® Daily Stock Analysis IBD® Indexes IBD®extra!

Newsletter Investing Tools ETF Center IBD® STOCK LISTS The IBD® 100 Screen Of The Day Stocks On The Move reported a fourth-quarter profit on Thursday, citing strong sales of newer products, even as sales of its lead product Zyprexa continued to decline.

Fourth-...

Will New Drugs Gild Lilly?

...Will New Drugs Gild Lilly?

- Motley Fool - MSNBC.comSkip navigationBusinessStocks & EconomyEarningsSuper Bowl BusinessPersonal FinanceTax TacticsReal EstateU.S.

BusinessIntl BusinessOil & EnergyAutomotiveAviationFood Inc.CNBC TVForbes.comBusinessWeekFinancial TimesMotley FoolSmall BusinessLocal BusinessU.S.

NewsWorld NewsBusinessSportsEntertainmentTech / ScienceHealthWeatherTravelBlogs Etc.Local NewsNewsweekMultimediaNews VideoMost PopularNBC NEWSMSNBC TVToday ShowNightly NewsMeet the PressDateline NBC  MSNBC Home » Business » Motley FoolWill New Drugs Gild Lilly?

Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow.By Stephen D.

Simpson, CFA (TMFWildWeasel) One way or another, drug development will cost you.

If you want to stay in the business of pharmaceuticals, you pretty much have to throw a lot of money into basic R&D, or else spend a lot of money on acquiring/licensing other companies and compounds.

Either way, it's going to take money and time.

Time is something of a mixed blessing for Eli Lilly(NYSE: LLY) right now, as the company tries to balance a weak late-stage pipeline with increasing contributions from newer approved drugs.

For the fourth quarter, Lilly's revenue rose 6% (on a 7% increase in volume), with newer drugs making up 20% of that total - up from 18% in the third quarter.

While sales were once again led by Zyprexa (which was down 5%), newer compounds like Cymbalta,

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news